<DOC>
	<DOCNO>NCT00926354</DOCNO>
	<brief_summary>Chemotherapy Induced Thrombocytopenia common side-effect bone marrow suppression result chemotherapy treatment . AS101 tellurium base small compound immunomodulating characteristic attribute direct inhibition anti-inflammatory cytokine IL-10 . AS101 previously show induce significant reduction thrombocytopenia accompany cancer therapy major toxicity . This phase II randomize open study evaluate efficacy AS101 treatment chemotherapy induce thrombocytopenia patient various solid tumor .</brief_summary>
	<brief_title>Application AS101 Treatment Thrombocytopenia Solid Tumor Patients</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Ammonium trichloro ( dioxoethylene-O , O'- ) tellurate</mesh_term>
	<criteria>Age ≥ 18 Appropriate histology solid tumor . Platelet count &lt; 70,000/μl . Performance Status ( PS ) 02 Adequate renal function : Serum creatinine ≤1.5 mg/dL Adequate liver function : Serum ( total ) bilirubin ≤ 1.5 ULN . AST , ALT ≤ 2.5 x ULN patient without liver metastasis , ≤ 5 x ULN patient liver metastasis . Albumin ≥ 2.5 g/dL ( Only patient receive AS101 ) . INR ≤ 1.5 PTT ≤ 1.5 x ULN ( Only patient receive AS101 ) . Patients unable provide fully inform consent . Women pregnant breast feeding . The patient participate another trial investigational drug do within 28 day prior pretreatment visit . The patient congestive heart failureNew York Heart Association ( CHFNYHA ) grade II high , and/or myocardial infarction within last 12 month , cardiac disorder opinion Investigator would put patient risk . The patient history chronic alcohol drug abuse within last 5 year . The patient clinically significant medical condition , psychiatric condition laboratory abnormality would , judgment Investigator , interfere patient 's ability participate trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
</DOC>